Your browser doesn't support javascript.
loading
Antidepressant Use and Lung Cancer Risk and Survival: A Meta-analysis of Observational Studies.
Lee, Eunkyung; Park, Yongho; Li, David; Rodriguez-Fuguet, Alice; Wang, Xiaochuan; Zhang, Wen Cai.
Afiliação
  • Lee E; Department of Health Sciences, College of Health Professions and Sciences, University of Central Florida, Orlando, Florida.
  • Park Y; College of Medicine, University of Central Florida, Orlando, Florida.
  • Li D; Department of Health Sciences, College of Health Professions and Sciences, University of Central Florida, Orlando, Florida.
  • Rodriguez-Fuguet A; Department of Cancer Division, Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida.
  • Wang X; School of Social Work, College of Health Professions and Sciences, University of Central Florida, Orlando, Florida.
  • Zhang WC; Department of Cancer Division, Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida.
Cancer Res Commun ; 3(6): 1013-1025, 2023 06.
Article em En | MEDLINE | ID: mdl-37377607
ABSTRACT
Recent preclinical studies have linked antidepressants (AD) to their potential anticancer effects in multiple cancers, but the impact on lung cancer remains unclear. This meta-analysis examined the associations between ADs and lung cancer incidence and survival. The Web of Science, Medline, CINAHL, and PsycINFO databases were searched to identify eligible studies published by June 2022. We conducted a meta-analysis using a random-effects model to compare the pooled risk ratio (RR) and 95% confidence interval (CI) in those treated with or without ADs. Heterogeneity was examined using Cochran Q test and inconsistency I2 statistics. The methodologic quality of the selected studies was assessed using the Newcastle-Ottawa Scale for observational studies. Our analysis, including 11 publications involving 1,200,885 participants, showed that AD use increased lung cancer risk by 11% (RR = 1.11; 95% CI = 1.02-1.20; I2 = 65.03%; n = 6) but was not associated with overall survival (RR = 1.04; 95% CI = 0.75-1.45; I2 = 83.40%; n = 4). One study examined cancer-specific survival. Subgroup analysis showed that serotonin and norepinephrine reuptake inhibitors (SNRIs) were associated with an increased lung cancer risk by 38% (RR = 1.38; 95% CI = 1.07-1.78; n = 2). The quality of selected studies was good (n = 5) to fair (n = 6). Our data analysis suggests that SNRIs were associated with an elevated risk of lung cancer, raising concerns regarding the use of AD treatment in patients vulnerable to lung cancer. The effects of ADs-particularly SNRIs-and their interplay with cigarette use and lung cancer risk in vulnerable patients merits further study.

Significance:

In this meta-analysis of 11 observational studies, we found evidence of a statistically significant association between the use of certain ADs and lung cancer risk. This effect merits further study, particularly as it relates to known environmental and behavioral drivers of lung cancer risk, such as air pollution and cigarette smoke.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores da Recaptação de Serotonina e Norepinefrina / Neoplasias Pulmonares Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Cancer Res Commun Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores da Recaptação de Serotonina e Norepinefrina / Neoplasias Pulmonares Tipo de estudo: Etiology_studies / Observational_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Cancer Res Commun Ano de publicação: 2023 Tipo de documento: Article